- Home
- PRTA vs RA Comparison
PRTA vs RA Comparison
Compare PRTA & RA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRTA
- RA
- Stock Information
- Founded
- PRTA 2012
- RA 2016
- Country
- PRTA Ireland
- RA United States
- Employees
- PRTA N/A
- RA 1260
- Industry
- PRTA Biotechnology: Pharmaceutical Preparations
- RA Investment Managers
- Sector
- PRTA Health Care
- RA Finance
- Exchange
- PRTA Nasdaq
- RA Nasdaq
- Market Cap
- PRTA 809.8M
- RA 715.0M
- IPO Year
- PRTA N/A
- RA N/A
- Fundamental
- Price
- PRTA $7.18
- RA $12.98
- Analyst Decision
- PRTA Buy
- RA
- Analyst Count
- PRTA 9
- RA 0
- Target Price
- PRTA $51.71
- RA N/A
- AVG Volume (30 Days)
- PRTA 1.6M
- RA 280.8K
- Earning Date
- PRTA 05-08-2025
- RA 01-01-0001
- Dividend Yield
- PRTA N/A
- RA 14.73%
- EPS Growth
- PRTA N/A
- RA N/A
- EPS
- PRTA N/A
- RA N/A
- Revenue
- PRTA $137,935,000.00
- RA N/A
- Revenue This Year
- PRTA N/A
- RA N/A
- Revenue Next Year
- PRTA $122.59
- RA N/A
- P/E Ratio
- PRTA N/A
- RA N/A
- Revenue Growth
- PRTA 54.55
- RA N/A
- 52 Week Low
- PRTA $8.00
- RA $11.89
- 52 Week High
- PRTA $25.42
- RA $17.32
- Technical
- Relative Strength Index (RSI)
- PRTA 30.36
- RA 54.20
- Support Level
- PRTA $6.47
- RA $12.93
- Resistance Level
- PRTA $8.08
- RA $12.99
- Average True Range (ATR)
- PRTA 0.72
- RA 0.08
- MACD
- PRTA 0.00
- RA 0.02
- Stochastic Oscillator
- PRTA 21.60
- RA 72.41
About PRTA Prothena Corporation plc
Prothena Corp PLC is a biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating rare neurodegenerative and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004).
About RA Brookfield Real Assets Income Fund Inc.
Brookfield Real Assets Income Fund Inc. is a diversified, closed-end management investment company. Its investment objective is to seek a high total return, through high current income and secondarily, through the growth of capital. The Fund seeks to achieve its investment objective by investing in the real asset class, which includes the following: Real Estate Securities; Infrastructure Securities; and Natural Resources Securities. The Firm manages separate accounts, registered funds, and opportunistic strategies for institutional and individual clients, including financial institutions, public and private pension plans, insurance companies, endowments and foundations, sovereign wealth funds, and high-net-worth investors.